196 related articles for article (PubMed ID: 19062080)
1. The effect of obesity on survival in patients with ovarian cancer.
Matthews KS; Straughn JM; Kemper MK; Hoskins KE; Wang W; Rocconi RP
Gynecol Oncol; 2009 Feb; 112(2):389-93. PubMed ID: 19062080
[TBL] [Abstract][Full Text] [Related]
2. Effect of obesity on survival in epithelial ovarian cancer.
Pavelka JC; Brown RS; Karlan BY; Cass I; Leuchter RS; Lagasse LD; Li AJ
Cancer; 2006 Oct; 107(7):1520-4. PubMed ID: 16941453
[TBL] [Abstract][Full Text] [Related]
3. Chemotherapy-related myelosuppression as a marker of survival in epithelial ovarian cancer patients.
Rocconi RP; Matthews KS; Kemper MK; Hoskins KE; Barnes MN
Gynecol Oncol; 2008 Feb; 108(2):336-41. PubMed ID: 18006047
[TBL] [Abstract][Full Text] [Related]
4. Impact of obesity on operative morbidity and clinical outcome in primary epithelial ovarian cancer after optimal primary tumor debulking.
Fotopoulou C; Richter R; Braicu EI; Kuhberg M; Feldheiser A; Schefold JC; Lichtenegger W; Sehouli J
Ann Surg Oncol; 2011 Sep; 18(9):2629-37. PubMed ID: 21394662
[TBL] [Abstract][Full Text] [Related]
5. Bowel resection at the time of primary debulking for epithelial ovarian carcinoma: outcomes in patients treated with platinum and taxane-based chemotherapy.
Estes JM; Leath CA; Straughn JM; Rocconi RP; Kirby TO; Huh WK; Barnes MN
J Am Coll Surg; 2006 Oct; 203(4):527-32. PubMed ID: 17000397
[TBL] [Abstract][Full Text] [Related]
6. Stage IVB endometrial cancer: does applying an ovarian cancer treatment paradigm result in similar outcomes? A case-control analysis.
Landrum LM; Moore KN; Myers TK; Lanneau GS; McMeekin DS; Walker JL; Gold MA
Gynecol Oncol; 2009 Feb; 112(2):337-41. PubMed ID: 19041126
[TBL] [Abstract][Full Text] [Related]
7. Carboplatin dosing in obese women with ovarian cancer: a Gynecologic Oncology Group study.
Wright JD; Tian C; Mutch DG; Herzog TJ; Nagao S; Fujiwara K; Powell MA
Gynecol Oncol; 2008 Jun; 109(3):353-8. PubMed ID: 18407341
[TBL] [Abstract][Full Text] [Related]
8. Neoadjuvant chemotherapy lessens surgical morbidity in advanced ovarian cancer and leads to improved survival in stage IV disease.
Hou JY; Kelly MG; Yu H; McAlpine JN; Azodi M; Rutherford TJ; Schwartz PE
Gynecol Oncol; 2007 Apr; 105(1):211-7. PubMed ID: 17239941
[TBL] [Abstract][Full Text] [Related]
9. Body mass index and survival in patients with epithelial ovarian cancer.
Suh DH; Kim HS; Chung HH; Kim JW; Park NH; Song YS; Kang SB
J Obstet Gynaecol Res; 2012 Jan; 38(1):70-6. PubMed ID: 21827578
[TBL] [Abstract][Full Text] [Related]
10. Body mass index as a prognostic factor in epithelial ovarian cancer and correlation with clinico-pathological factors.
Skírnisdóttir I; Sorbe B
Acta Obstet Gynecol Scand; 2010; 89(1):101-7. PubMed ID: 19878086
[TBL] [Abstract][Full Text] [Related]
11. The effect of maximal surgical cytoreduction on sensitivity to platinum-taxane chemotherapy and subsequent survival in patients with advanced ovarian cancer.
Eisenhauer EL; Abu-Rustum NR; Sonoda Y; Aghajanian C; Barakat RR; Chi DS
Gynecol Oncol; 2008 Feb; 108(2):276-81. PubMed ID: 18063020
[TBL] [Abstract][Full Text] [Related]
12. Effect of body mass index on mortality of patients with lymphoma undergoing autologous hematopoietic cell transplantation.
Navarro WH; Loberiza FR; Bajorunaite R; van Besien K; Vose JM; Lazarus HM; Rizzo JD
Biol Blood Marrow Transplant; 2006 May; 12(5):541-51. PubMed ID: 16635789
[TBL] [Abstract][Full Text] [Related]
13. Tertiary cytoreductive surgery in recurrent ovarian cancer: selection criteria and survival outcome.
Karam AK; Santillan A; Bristow RE; Giuntoli R; Gardner GJ; Cass I; Karlan BY; Li AJ
Gynecol Oncol; 2007 Feb; 104(2):377-80. PubMed ID: 17014899
[TBL] [Abstract][Full Text] [Related]
14. Hyperandrogenism, mediated by obesity and receptor polymorphisms, promotes aggressive epithelial ovarian cancer biology.
Li AJ; Elmore RG; Pavelka JC; Karlan BY
Gynecol Oncol; 2007 Dec; 107(3):420-3. PubMed ID: 17825390
[TBL] [Abstract][Full Text] [Related]
15. The role of secondary cytoreductive surgery for recurrent mucinous epithelial ovarian cancer (mEOC).
Cheng X; Jiang R; Li ZT; Tang J; Cai SM; Zhang ZY; Tian WJ; Zang RY
Eur J Surg Oncol; 2009 Oct; 35(10):1105-8. PubMed ID: 19443175
[TBL] [Abstract][Full Text] [Related]
16. Neoadjuvant intraarterial chemotherapy and embolization in treatment of advanced ovarian epithelial carcinoma.
Liu EL; Mi RR
Chin Med J (Engl); 2004 Oct; 117(10):1547-51. PubMed ID: 15498381
[TBL] [Abstract][Full Text] [Related]
17. Extreme drug resistance assay results do not influence survival in women with epithelial ovarian cancer.
Karam AK; Chiang JW; Fung E; Nossov V; Karlan BY
Gynecol Oncol; 2009 Aug; 114(2):246-52. PubMed ID: 19500821
[TBL] [Abstract][Full Text] [Related]
18. Prognostic impact of hemoglobin levels before and during carboplatin/taxane-based chemotherapy in patients with primary invasive epithelial ovarian cancer.
Eichbaum MH; Weiss LM; Bruckner T; Schneeweiss A; Sinn HP; Gebauer G; Fersis N; Kussmaul J; Sohn C
Med Sci Monit; 2009 Apr; 15(4):CR156-63. PubMed ID: 19333199
[TBL] [Abstract][Full Text] [Related]
19. Impact of body mass index on treatment outcomes in endometrial cancer patients receiving doxorubicin and cisplatin: a Gynecologic Oncology Group study.
Modesitt SC; Tian C; Kryscio R; Thigpen JT; Randall ME; Gallion HH; Fleming GF;
Gynecol Oncol; 2007 Apr; 105(1):59-65. PubMed ID: 17150247
[TBL] [Abstract][Full Text] [Related]
20. The impact of obesity on outcomes following pancreatectomy for malignancy.
Benns M; Woodall C; Scoggins C; McMasters K; Martin R
Ann Surg Oncol; 2009 Sep; 16(9):2565-9. PubMed ID: 19557479
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
